IP Verse

Pharmaceutical Composition Comprising Hmg-Coa Reductase Inhibitors And Fenofibrate - EP3833335B1

PatentPatent Analysis

EP3833335

INTAS PHARMACEUTICALS
Application Number
EP20764155A
Filing Date
Jul 30, 2020
Status
Granted And Under Opposition
Jul 29, 2022
Grant Date
Aug 31, 2022
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP2978426B1
EP2917192B1

Bibliography

The patent EP3833335B1 was granted to Intas Pharmaceuticals on Aug 31, 2022 following the initial filing on Jul 30, 2020 under the application number EP20764155A . The current legal status of the patent is Granted And Under Opposition.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

VIATRIS HEALTHCARE LDAJun 5, 2024INTERVENTION WITHDRAWN
ELKINGTON AND FIFEMay 30, 2023WITHDRAWN

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents